Cross-over trials in Statistics in Medicine: The first '25' years

Statistics in Medicine

Volumn 25, Issue 20, 2006, Pages 3430-3442

  Senn, Stephen ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Baselines; Binary data; Bioequivalence; Carry over; Survival analysis

Indexed keywords

DRUG;

ARTICLE; BIOEQUIVALENCE; BIOSTATISTICS; CLINICAL TRIAL; DATA ANALYSIS; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG INDUSTRY; FOOD AND DRUG ADMINISTRATION; HUMAN; INFORMATION PROCESSING; LICENCE; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; MEDICAL LITERATURE; METHODOLOGY; SCIENTIFIC LITERATURE; STATISTICAL ANALYSIS; SURVIVAL;

CROSS-OVER STUDIES; JOURNALISM, MEDICAL; UNITED STATES;

EID: 33750041062     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.2706     Document Type: Article

References (56)

1. Baskerville JC, Toogood JH, Mazza J, Jennings B. Clinical trials designed to evaluate therapeutic preferences. Statistics in Medicine 1984; 3:45-55.
2. Guyatt GH, Heyting AH, Jaeschke R, Keller J, Adachi JD, Roberts RS. N of 1 trials for investigating new drugs. Controlled Clinical Trials 1990; 11:88-100.
3. Marshall RJ, Jackson RT. Analysis of case-crossover designs. Statistics in Medicine 1993; 12:2333-2341.
4. Heitjan DF. Ignorability and bias in clinical trials. Statistics in Medicine 1999; 18:2421-2434.
5. Senn SJ. Cross-Over Trials in Clinical Research. Wiley: Chichester, 2002.
6. Freeman P. The performance of the two-stage analysis of two-treatment, two-period cross-over trials. Statistics in Medicine 1989; 8:1421-1432.
7. Grizzle JE. The two-period change over design and its use in clinical trials. Biometrics 1965; 21:467-480.
8. Hills M, Armitage P. The two-period cross-over clinical trial. British Journal of Clinical Pharmacology 1979; 8:7-20.
9. Jones B, Lewis JA. The case for cross-over trials in phase III [see comments]. Statistics in Medicine 1995; 14:1025-1038.
10. Senn SJ. The case for cross-over trials in phase III [letter; comment]. Statistics in Medicine 1997; 16:2021-2022.
11. Senn SJ. The AB/BA cross-over: how to perform the two-stage analysis if you can't be persuaded that you shouldn't. In Liber Amicorum Roel van Strik, Hansen B, de Ridder M (eds). Erasmus University: Rotterdam, 1996; 93-100.
12. Wang SJ, Hung HM. Use of two-stage test statistic in the two-period crossover trials. Biometrics 1997; 53: 1081-1091.
13. Kenward MG, Jones B. The analysis of data from 2 × 2 cross-over trial with baseline measurements. Statistics in Medicine 1987; 6:911-926.
14. Ratkowsky DA, Evans MA, Alldredge JR. Cross-Over Experiments: Design, Analysis, and Application. Marcel-Dekker: New York, 1993.
15. Senn SJ. An unreasonable prejudice against modelling? Pharmaceutical Statistics 2005; 4:87-89.
16. Liang KY, Zeger SL. Longitudinal data analysis of continuous and discrete responses for pre-post designs. Sankhya-the Indian Journal of Statistics, Series B 2000; 62:134-148.
17. Senn SJ. The AB/BA crossover: past, present and future? Statistical Methods in Medical Research 1994; 3: 303-324.
18. Kenward M, Jones B. A log-linear model for binary data. Applied Statistics 1987; 36:192-204.
19. Jones B, Kenward MG. Design and Analysis of Cross-Over Trials. Chapman & Hall: London, 1989.
20. Ezzet F, Whitehead J. A random effects model for ordinal response from a cross-over trial. Statistics in Medicine 1991; 10:901-907.
21. Ezzet F, Whitehead J. A random effects model for binary data from cross-over trials. Applied Statistics 1992; 41:117-126.
22. McCullagh P. Regression models for ordinal data. Journal of the Royal Statistical Society, Series B 1980; 42:109-142.
23. Senn SJ. A random effects model for ordinal responses from a crossover trial [letter; comment]. Statistics in Medicine 1993; 12:2147-2151.
24. Mainland D. Elementary Medical Statistics. W. B. Saunders: Philadelphia, PA, 1963.
25. Gart JJ. An exact test for comparing matched proportions in cross-over designs. Biometrika 1969; 56:75-80.
26. Zeger SL, Liang KY. An overview of methods for the analysis of longitudinal data. Statistics in Medicine 1992; 11:1825-1839.
27. Senn SJ. The use of baselines in clinical trials of bronchodilators. Statistics in Medicine 1989; 8:1339-1350.
28. France LA, Lewis JA, Kay R. The analysis of failure time data in cross-over studies. Statistics in Medicine 1991; 8:1421-1432.
29. Ford I, Norrie J, Ahmadi S. Model inconsistency, illustrated by the Cox proportional hazards model. Statistics in Medicine 1995; 14:735-746.
30. Feingold M, Gillespie BW. Cross-over trials with censored data. Statistics in Medicine 1996; 15:953-967.
31. Hougaard P. Analysis of Multivariate Survival Data. Springer: New York, 2000.
32. Fletcher DJ, Lewis SM, Matthews JN. Factorial designs for crossover clinical trials. Statistics in Medicine 1990; 9:1121-1129.
33. Senn SJ. Is the 'simple carry-over' model useful? [Published erratum appears in Statistics in Medicine 1992; 11(12):1619]. Statistics in Medicine 1992; 11:715-726.
34. Jones B, Donev AN. Modelling and design of cross-over trials. Statistics in Medicine 1996; 15:1435-1446.
35. John JA, Russell KG, Whitaker D. Crossover: an algorithm for the construction of efficient cross-over designs. Statistics in Medicine 2004; 23:2645-2658.
36. Senn SJ. Letter to the editor: misunderstandings regarding clinical cross-over trials. Statistics in Medicine 2005; 24:3675-3678.
37. Sheiner LB, Hashimoto Y, Beal SL. A simulation study comparing designs for dose-ranging. Statistics in Medicine 1991; 10:303-321.
38. Fleiss JL. Letter to the editor. Biometrics 1986; 42:449-450.
39. Fleiss JL. A critique of recent research on the two-treatment cross-over design. Controlled Clinical Trials 1989; 10:237-243.
40. Senn SJ, Lambrou D. Robust and realistic approaches to carry-over. Statistics in Medicine 1998; 17:2849-2864.
41. Sheiner LB. Bioequivalence revisited. Statistics in Medicine 1992; 11:1777-1788.
42. Schall R, Luus HG. On population and individual bioequivalence. Statistics in Medicine 1993; 12:1109-1124.
43. Hauck WW, Anderson S. Individual bioequivalence - what matters to the patient. Statistics in Medicine 1991; 10:959-960.
44. Anderson S, Hauck WW. Consideration of individual bioequivalence. Journal of Pharmacokinetics and Biopharmaceutics 1990; 18:259-273.
45. Hauck WW, Anderson S. Types of bioequivalence and related statistical considerations. International Journal of Clinical Pharmacology and Therapeutics 1992; 30:181-187.
46. Rhodes C. Bioequivalence evaluation - possible future development. Clinical Research and Regulatory Affairs 1994; 11:181-192.
47. Senn SJ. Statistical Issues in Drug Development. Wiley: Chichester, 1997.
48. Senn SJ. Statistical issues in bioequivalence. Statistics in Medicine 2001; 20:2785-2799.
49. Senn SJ, Hildebrand H. Crossover trials, degrees of freedom, the carryover problem and its dual. Statistics in Medicine 1991; 10:1361-1374.
50. Shumaker RC, Metzler CM. The phenytoin trial is a case study of 'individual bioequivalence'. Drug Information Journal 1998; 32:1063-1072.
51. Brown HK, Kempton RA. The application of REML in clinical trials. Statistics in Medicine 1994; 13:1601-1617.
52. Putt M, Chinchilli VM. A mixed effects model for the analysis of repeated measures cross-over studies. Statistics in Medicine 1999; 18:3037-3058.
53. Senn SJ. Individual therapy: new dawn or false dawn. Drug Information Journal 2001; 35:1479-1494.
54. Senn SJ. Author's reply to Walter and Guyatt. Drug Information Journal 2003; 37:7-10.
55. Senn SJ, Lee S. The analysis of the AB/BA cross-over trial in the medical literature. Pharmaceutical Statistics 2004; 3:123-131.
56. Lee SH-S. Use of the two-stage procedure for analysis of cross-over trials in four aspects of medical statistics. Ph.D. Thesis, University of London, London, 2005.